The hearing giant reported 7% organic revenue growth for the financial year, though macroeconomic conditions have led the firm to be more conservative with next year’s estimates.

The hearing aid manufacturer is expecting growth in fiscal 2022/2023 to be under its recent annual result due to a market decline that looks to continue into the future, says CEO Eric Bernard.

After a busy year at the Danish drugmaker, the firm has decided to give something back to its workers in the shape of four days extra vacation time.

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.